Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1957 1
1960 1
1963 2
1969 1
1971 1
1973 1
1974 2
1975 1
1976 1
1978 1
1979 1
1980 8
1981 2
1982 1
1983 7
1984 3
1985 5
1986 3
1987 5
1988 4
1989 9
1990 6
1991 9
1992 14
1993 3
1994 4
1995 8
1996 12
1997 13
1998 16
1999 10
2000 4
2001 8
2002 15
2003 12
2004 17
2005 21
2006 22
2007 29
2008 41
2009 39
2010 47
2011 39
2012 39
2013 50
2014 48
2015 48
2016 52
2017 69
2018 65
2019 55
2020 60
2021 69
2022 79
2023 65
2024 72
2025 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,109 results

Results by year

Filters applied: . Clear all
Page 1
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. Nast A, et al. Among authors: de jong e. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. doi: 10.1111/jdv.16915. J Eur Acad Dermatol Venereol. 2020. PMID: 33349983
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. Nast A, et al. Among authors: de jong e. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317. doi: 10.1111/jdv.16926. J Eur Acad Dermatol Venereol. 2021. PMID: 33547728 Free article.
Intestinal parasites.
Jong E. Jong E. Prim Care. 2002 Dec;29(4):857-77. doi: 10.1016/s0095-4543(02)00047-7. Prim Care. 2002. PMID: 12687897 Review.
Five decades of Dutch immunology.
Germeraad WT, de Jong EC, Trouw LA. Germeraad WT, et al. Among authors: de jong ec. Immunol Lett. 2014 Dec;162(2 Pt B):83-4. doi: 10.1016/j.imlet.2014.10.006. Epub 2014 Oct 18. Immunol Lett. 2014. PMID: 25455593 No abstract available.
Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EMW, de Smet AMGA, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW. de Jong E, et al. Lancet Infect Dis. 2016 Jul;16(7):819-827. doi: 10.1016/S1473-3099(16)00053-0. Epub 2016 Mar 2. Lancet Infect Dis. 2016. PMID: 26947523 Clinical Trial.
Mitochondrial protein import clogging as a mechanism of disease.
Coyne LP, Wang X, Song J, de Jong E, Schneider K, Massa PT, Middleton FA, Becker T, Chen XJ. Coyne LP, et al. Among authors: de jong e. Elife. 2023 May 2;12:e84330. doi: 10.7554/eLife.84330. Elife. 2023. PMID: 37129366 Free PMC article.
Granulocytes as modulators of dendritic cell function.
Breedveld A, Groot Kormelink T, van Egmond M, de Jong EC. Breedveld A, et al. Among authors: de jong ec. J Leukoc Biol. 2017 Oct;102(4):1003-1016. doi: 10.1189/jlb.4MR0217-048RR. Epub 2017 Jun 22. J Leukoc Biol. 2017. PMID: 28642280 Review.
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.
Kidman J, Zemek RM, Sidhom JW, Correa D, Principe N, Sheikh F, Fear VS, Forbes CA, Chopra A, Boon L, Zaitouny A, de Jong E, Holt RA, Jones M, Millward MJ, Lassmann T, Forrest ARR, Nowak AK, Watson M, Lake RA, Lesterhuis WJ, Chee J. Kidman J, et al. Among authors: de jong e. Oncoimmunology. 2024 Apr 26;13(1):2345859. doi: 10.1080/2162402X.2024.2345859. eCollection 2024. Oncoimmunology. 2024. PMID: 38686178 Free PMC article.
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Thomas SE, Seyger MMB, Mangnus JE, Otero ME, Gostynski AH, Njoo MD, Ossenkoppele PM, Haeck IM, Hendricksen-Roelofzen JHJ, Körver JEM, Dodemont SRP, Tupker RA, Berends MAM, Weppner-Parren LMJT, Keijsers RRMC, Oostveen AM, Peters B, Mommers R, van Doorn MBA, Tjioe M, Veldkamp WR, Kuijpers ALA, Kleinpenning MM, de Jong EMGJ, van den Reek JMPA. Thomas SE, et al. Among authors: de jong emgj. Am J Clin Dermatol. 2024 Jul;25(4):685-688. doi: 10.1007/s40257-024-00868-x. Epub 2024 May 27. Am J Clin Dermatol. 2024. PMID: 38802618 No abstract available.
Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial.
van Huizen AM, van der Kraaij GE, Busard CI, Ouwerkerk W, van den Reek JMPA, Menting SP, Prens EP, Rispens T, de Vries A, de Jong EMGJ, Lambert J, van Doorn MBA, Spuls PI. van Huizen AM, et al. Among authors: de jong emgj. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1815-1824. doi: 10.1111/jdv.19089. Epub 2023 Apr 17. J Eur Acad Dermatol Venereol. 2023. PMID: 37014287 Clinical Trial.
1,109 results